

# Transcranial Magnetic Stimulation for MCI

NCT05992831

---

Status	RECRUITING
Phase	Not Applicable
Sponsor	Medical University of South Carolina
Enrollment	60 participants

## Plain Language Summary

---

This study is testing whether repetitive transcranial magnetic stimulation (rTMS — a non-invasive procedure that uses magnetic pulses to stimulate the brain) can help people with mild cognitive impairment (MCI), which is early memory and thinking difficulties that can lead to dementia.

**\*\*You may be eligible if...\*\***

- You are between 60 and 85 years old
- English is your first or primary language
- You have been diagnosed with mild cognitive impairment (MCI)
- You have a close person (spouse, family member, or friend) who sees you at least once a week and can act as a study companion
- You are on a stable medication dose

**\*\*You may NOT be eligible if...\*\***

- You are outside the 60–85 age range
- You do not have a close contact able to participate
- You have conditions that affect your ability to communicate or complete assessments

Talk to your doctor to see if this trial is right for you.

## Key Eligibility Criteria

---

### Inclusion (6)

- i. Age 60-85 (inclusive). ii. English as a first/primary language. iii. Adequate sensorimotor function and verbal expressive abilities to complete all assessments.
- iv. Must have a Co-Participant (e.g. spouse, adult child or relative, sibling, cohabitor, friend, caregiver) who has at least weekly in-person contact with the participant and is willing to participate in the study as a collateral informant.
- v. Is on fixed pharmacotherapy (i.e. a stable dose of medication/s) for at least 4 weeks prior to enrollment. Cholinesterase inhibitors, NMDA receptor antagonists, and antidepressants are allowed if on a stable regimen for at least 4 weeks prior to enrollment. Prior treatment with anti-amyloid monoclonal antibody therapy is acceptable if last infusion was at least 8 weeks prior to enrollment. Prior TMS treatment is acceptable if last stimulation session was at least 24 weeks prior to enrollment.
- vi. A documented diagnosis of MCI per NIA-AA criteria or Mild Neurocognitive Disorder per DSM-5 criteria by a healthcare provider within the past 2 years, with a presumed etiology of either (or both): vi.a Possible or probable AD vi.b Chronic cerebrovascular disease (CVD), specifically small vessel disease as defined in STRIVE-2 which includes small subcortical infarcts, lacunes, white matter hyperintensities, perivascular spaces, cerebral micro bleeds, cortical superficial siderosis, or cortical cerebral microinfarcts. .
- vii. Met actuarial neuropsychological criteria for MCI within the past 2 years (i.e. e2 impaired scores within one cognitive domain, or e1 impaired scores in e3 domains, where an impaired score is defined as d16th percentile using appropriate demographically-corrected norms).

... and 1 more (see full listing online)

### Exclusion (7)

<https://clinicaltrials.gov/study/NCT05992831>

- i. A TICS score of d 19 suggestive of dementia. ii. Prior diagnosis of Dementia (NIA-AA) or Major Neurocognitive Disorder (DSM-5).

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).

- iii. Daily/weekly anticholinergic or sedative use. Stimulants may be allowed pending investigator review.
  - iv. History of significant or unstable condition/s or treatments for these condition/s that may impact cognition (as determined by the study investigators) such as significant cardiac (e.g. heart failure), infectious (e.g. HIV, urinary tract infection), or metabolic disease (e.g. labile diabetes), cancer (e.g. brain cancer, chemotherapy-induced cognitive impairment), developmental disorder (e.g. autism spectrum disorder, intellectual disability), or other neurologic disease (e.g. movement disorder, multiple sclerosis, moderate to severe brain injury, seizures).
  - v. Current treatment for AD/MCI with monoclonal antibody therapy or plan to initiate treatment within three months of enrollment.
  - vi. Current use of any implanted brain stimulation device. vii. Enrolled in a clinical trial or has received an investigational medication or device in the last 30 days.
- ... and 2 more (see full listing online)

## Locations (1 total)

---

Medical University of South Carolina, Charleston, South Carolina, United States